NTAGI

Mumbai: Biological E (BE) said it has submitted Corbevax to WHO for emergency use listing (EUL) and "detailed review" of the application is underway. A top executive of the Hyderabad-based vaccine maker said a WHO inspection team audited…

NEW DELHI: The National Technical Advisory Group on Immunisation's Covid working group has reviewed the data of Biological E's Corbevax to allow it as booster for those aged 18 and above fully vaccinated with Covishield or Covaxin,…

The Standing Technical Sub-Committee (STSC) of the NTAGI on Friday recommended the use of Bharat Biotech's Covaxin and Corbevax vaccines for Covid-19 for children aged between five and 12 years. Data of Biological E's Corbevax and Bharat…

The National Technical Advisory Group on Immunisation (NTAGI) is likely to review the data of Corbevax to consider allowing it to be administered to those fully vaccinated with Covishield or Covaxin, amid emergence of new sub lineage in…

NEW DELHI: In a move that is expected to enhance coverage of booster or “precaution dose” against Covid-19, the health ministryhas reduced the gap between the second and third vaccine shots to six months from the nine months at present.…

NEW DELHI: The Centre on Wednesday reduced the gap for administration of Covid vaccine booster doses from existing 9 months or 39 weeks to 6 months or 26 weeks. The Union health ministry said that as per the recommendation, it has been…

NEW DELHI: Allowing Biological E's Corbevax as a booster for those fully vaccinated against Covid-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. The…

By Payal Banerjee New Delhi, Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses…

A new study published in the Lancet has revealed that AstraZeneca's Covid-19 vaccine, which is being used in India as Covishield, is well tolerated and immunogenic in children aged 6-17 years. "No safety concerns were raised in this…